Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
EPRX
Stock Latest News
Company Announcements
Eupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI
3d ago
6K
EPRX
Premium
Ratings
Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16
4d ago
EPRX
Premium
Ratings
Buy Rating Reiterated on Eupraxia Ahead of Key EP-104GI Trial Data; $11 Price Target Maintained
4d ago
EPRX
Premium
Ratings
Analyst Maintains Buy on Eupraxia as Lead Asset EP-104GI Shows Strong Efficacy, Safety and Expanding Esophageal Opportunities
4d ago
EPRX
Premium
Company Announcements
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects
5d ago
EPRX
Premium
The Fly
Eupraxia Pharmaceuticals files $300M mixed securities shelf
10d ago
EPRX
Premium
Pre-Earnings
EPRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
11d ago
EPRX
Premium
Ratings
David Martin Reiterates Buy on Eupraxia Pharmaceuticals, Citing Strong KOL Support for EP-104GI’s Commercialization Potential
13d ago
EPRX
Premium
Ratings
Sam Slutsky Reiterates Buy Rating on EP-104GI Developer, Maintains $16 Price Target
16d ago
EPRX
Premium
Ratings
Analyst Reiterates Buy on EPRX, Keeps EP-104GI Upside Reflected in Unchanged $11 Price Target
16d ago
EPRX
Premium
Ratings
Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook
16d ago
EPRX
Premium
Ratings
Buy Rating Reaffirmed on EPRX as EP-104GI Catalyst Nears and $16 Price Target Remains Unchanged
26d ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone
1M ago
6K
EPRX
Premium
The Fly
Eupraxia chief scientific and operating officer Amanda Malone steps down
1M ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances
1M ago
6K
EPRX
Premium
The Fly
Oppenheimer starts Eupraxia at Outperform, sees upside from EoE
2M ago
EPRX
Premium
The Fly
Eupraxia Pharmaceuticals initiated with an Outperform at Oppenheimer
2M ago
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Shareholders Back Board Slate and Auditor at June 18 AGM
2M ago
6K
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K
3M ago
6K
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders
3M ago
6K
EPRX
Premium
Company Announcements
Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference
3M ago
6K
EPRX
Premium
The Fly
Eupraxia Pharmaceuticals initiated with a Buy at Stifel
3M ago
EPRX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
